We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: May 15, 2009
Last Update Posted: July 25, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Asahi Kasei Pharma Corporation
This will be a Phase II, multi-centre study consisting of 2 parts. Part 1: Clinical Pharmacology Study (drug-drug interaction between AK106-001616 and methotrexate) Part 2: Proof of Concept Study

Condition Intervention Phase
Rheumatoid Arthritis Drug: AK106-001616 Drug: Placebo Drug: Active comparator Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Asahi Kasei Pharma Corporation:

Estimated Enrollment: 130
Study Start Date: May 2009
Study Completion Date: July 2010
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AK106-001616 Drug: AK106-001616
Part1: Dose escalation Part2: Dose expansion
Placebo Comparator: Placebo
Part1: AK106-001616 and Placebo
Drug: Placebo
Active Comparator: Active comparator
Part2: AK106-001616 and Active comparator
Drug: Active comparator


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of RA (class I to III)
  • Stable dose of methotrexate (at least 12 weeks)

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Abnormal screening laboratory test values considered to be clinically significant
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00902369

Czech Republic
Hlucin, Czech Republic
Praha 2, Czech Republic
Uherske Hradiste, Czech Republic
Frankfurt, Hessen, Germany
Berlin, Germany
Hamburg, Germany
Budapest, Hungary
Érd, Hungary
Vilnius, Lithuania
Bucharest, Romania
United Kingdom
Cambridge, Cambridgeshire, United Kingdom
Sheffield, South Yorkshire, United Kingdom
Sponsors and Collaborators
Asahi Kasei Pharma Corporation
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Asahi Kasei Pharma Corporation
ClinicalTrials.gov Identifier: NCT00902369     History of Changes
Other Study ID Numbers: AK106 II-01
First Submitted: May 14, 2009
First Posted: May 15, 2009
Last Update Posted: July 25, 2016
Last Verified: July 2010

Keywords provided by Asahi Kasei Pharma Corporation:

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases